Review



s parameter data  (Mini-Circuits)


Bioz Verified Symbol Mini-Circuits is a verified supplier
Bioz Manufacturer Symbol Mini-Circuits manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Mini-Circuits s parameter data
    S Parameter Data, supplied by Mini-Circuits, used in various techniques. Bioz Stars score: 94/100, based on 18 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/s parameter data/product/Mini-Circuits
    Average 94 stars, based on 18 article reviews
    s parameter data - by Bioz Stars, 2026-04
    94/100 stars

    Images



    Similar Products

    99
    ATCC v1 sbp gfp hiv 1 reporter virus
    V1 Sbp Gfp Hiv 1 Reporter Virus, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/v1 sbp gfp hiv 1 reporter virus/product/ATCC
    Average 99 stars, based on 1 article reviews
    v1 sbp gfp hiv 1 reporter virus - by Bioz Stars, 2026-04
    99/100 stars
      Buy from Supplier

    94
    Mini-Circuits s parameter data
    S Parameter Data, supplied by Mini-Circuits, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/s parameter data/product/Mini-Circuits
    Average 94 stars, based on 1 article reviews
    s parameter data - by Bioz Stars, 2026-04
    94/100 stars
      Buy from Supplier

    94
    Mini-Circuits mhz
    Mhz, supplied by Mini-Circuits, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mhz/product/Mini-Circuits
    Average 94 stars, based on 1 article reviews
    mhz - by Bioz Stars, 2026-04
    94/100 stars
      Buy from Supplier

    94
    Mini-Circuits sbp
    Sbp, supplied by Mini-Circuits, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sbp/product/Mini-Circuits
    Average 94 stars, based on 1 article reviews
    sbp - by Bioz Stars, 2026-04
    94/100 stars
      Buy from Supplier

    94
    Mini-Circuits mini circuits sbp
    Mini Circuits Sbp, supplied by Mini-Circuits, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mini circuits sbp/product/Mini-Circuits
    Average 94 stars, based on 1 article reviews
    mini circuits sbp - by Bioz Stars, 2026-04
    94/100 stars
      Buy from Supplier

    94
    Mini-Circuits mini circuits sbp21 4
    Mini Circuits Sbp21 4, supplied by Mini-Circuits, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mini circuits sbp21 4/product/Mini-Circuits
    Average 94 stars, based on 1 article reviews
    mini circuits sbp21 4 - by Bioz Stars, 2026-04
    94/100 stars
      Buy from Supplier

    90
    Ruixi Biotech Co sbp peptide
    Sbp Peptide, supplied by Ruixi Biotech Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sbp peptide/product/Ruixi Biotech Co
    Average 90 stars, based on 1 article reviews
    sbp peptide - by Bioz Stars, 2026-04
    90/100 stars
      Buy from Supplier

    93
    MedChemExpress sbp solution
    Sbp Solution, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sbp solution/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    sbp solution - by Bioz Stars, 2026-04
    93/100 stars
      Buy from Supplier

    93
    TargetMol sbp 7455
    Sbp 7455, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sbp 7455/product/TargetMol
    Average 93 stars, based on 1 article reviews
    sbp 7455 - by Bioz Stars, 2026-04
    93/100 stars
      Buy from Supplier

    93
    TargetMol ulk1 inhibitor sbp 7455
    ( A ) Schematic illustration of the inducible and conditional <t>Ulk1</t> knockout mouse MPN model used, and analyses performed. (BMT – bone marrow transplant) ( B ) Hemoglobin (Hb) levels, ( C ) hematocrit (HCT) percentage and ( D ) red blood cell (RBC) counts in peripheral blood of Ulk1 +/+ Jak2 V617F and Ulk1 FL/FL Jak2 V617F recipient mice are shown for pre- (day 21) and post- (day 42) pIpC injection. ( E ) Spleen weight and ( F ) percentage of GFP + splenocytes three weeks post pIpC injection of the recipient mice. ( G ) Percentage of GFP + ( G-i ) Ter119 med CD71 high proerythroblasts (R1), ( G-ii ) Ter119 high CD71 high basophilic erythroblasts (R2), and ( G-iii ) Ter119 high CD71 med late basophilic and polychromatophilic erythroblasts (R3) and Ter119 high CD71 low orthochromatophilic erythroblasts (R4) in the spleen of recipient mice three weeks post pIpC injection. ( H ) Percentage of GFP + bone marrow (BM) cells three weeks post pIpC injection of the recipient mice. Percentage of GFP + ( I-i ) R1, ( I-ii ) R2, and ( I-iii ) R3+R4 cells in the BM of recipient mice three weeks post pIpC injection. ( B-I ) Box plots show distribution of data from 6 mice per group. ( B-D ) Mixed effects models were used to analyze these data, with Hb, HCT or RBC counts as the outcome variable, and time (pre- and post-pIpC), genotype and their interaction as fixed effects, and a mouse random effect to account for within-mouse correlation between repeated measurements. Fisher’s LSD approach was used, and pairwise comparison p -values were not adjusted. ( E-I ) Statistical analyses were performed using Mann-Whitney test. ( B-I ) Statistically significant p -values are reported. ns - not significant. See also supplemental figures 1 – 3 .
    Ulk1 Inhibitor Sbp 7455, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ulk1 inhibitor sbp 7455/product/TargetMol
    Average 93 stars, based on 1 article reviews
    ulk1 inhibitor sbp 7455 - by Bioz Stars, 2026-04
    93/100 stars
      Buy from Supplier

    Image Search Results


    ( A ) Schematic illustration of the inducible and conditional Ulk1 knockout mouse MPN model used, and analyses performed. (BMT – bone marrow transplant) ( B ) Hemoglobin (Hb) levels, ( C ) hematocrit (HCT) percentage and ( D ) red blood cell (RBC) counts in peripheral blood of Ulk1 +/+ Jak2 V617F and Ulk1 FL/FL Jak2 V617F recipient mice are shown for pre- (day 21) and post- (day 42) pIpC injection. ( E ) Spleen weight and ( F ) percentage of GFP + splenocytes three weeks post pIpC injection of the recipient mice. ( G ) Percentage of GFP + ( G-i ) Ter119 med CD71 high proerythroblasts (R1), ( G-ii ) Ter119 high CD71 high basophilic erythroblasts (R2), and ( G-iii ) Ter119 high CD71 med late basophilic and polychromatophilic erythroblasts (R3) and Ter119 high CD71 low orthochromatophilic erythroblasts (R4) in the spleen of recipient mice three weeks post pIpC injection. ( H ) Percentage of GFP + bone marrow (BM) cells three weeks post pIpC injection of the recipient mice. Percentage of GFP + ( I-i ) R1, ( I-ii ) R2, and ( I-iii ) R3+R4 cells in the BM of recipient mice three weeks post pIpC injection. ( B-I ) Box plots show distribution of data from 6 mice per group. ( B-D ) Mixed effects models were used to analyze these data, with Hb, HCT or RBC counts as the outcome variable, and time (pre- and post-pIpC), genotype and their interaction as fixed effects, and a mouse random effect to account for within-mouse correlation between repeated measurements. Fisher’s LSD approach was used, and pairwise comparison p -values were not adjusted. ( E-I ) Statistical analyses were performed using Mann-Whitney test. ( B-I ) Statistically significant p -values are reported. ns - not significant. See also supplemental figures 1 – 3 .

    Journal: Molecular and cellular biology

    Article Title: Loss of function mouse models reveal a novel regulatory function for ULK1 in myeloproliferative neoplasms

    doi: 10.1080/10985549.2025.2529837

    Figure Lengend Snippet: ( A ) Schematic illustration of the inducible and conditional Ulk1 knockout mouse MPN model used, and analyses performed. (BMT – bone marrow transplant) ( B ) Hemoglobin (Hb) levels, ( C ) hematocrit (HCT) percentage and ( D ) red blood cell (RBC) counts in peripheral blood of Ulk1 +/+ Jak2 V617F and Ulk1 FL/FL Jak2 V617F recipient mice are shown for pre- (day 21) and post- (day 42) pIpC injection. ( E ) Spleen weight and ( F ) percentage of GFP + splenocytes three weeks post pIpC injection of the recipient mice. ( G ) Percentage of GFP + ( G-i ) Ter119 med CD71 high proerythroblasts (R1), ( G-ii ) Ter119 high CD71 high basophilic erythroblasts (R2), and ( G-iii ) Ter119 high CD71 med late basophilic and polychromatophilic erythroblasts (R3) and Ter119 high CD71 low orthochromatophilic erythroblasts (R4) in the spleen of recipient mice three weeks post pIpC injection. ( H ) Percentage of GFP + bone marrow (BM) cells three weeks post pIpC injection of the recipient mice. Percentage of GFP + ( I-i ) R1, ( I-ii ) R2, and ( I-iii ) R3+R4 cells in the BM of recipient mice three weeks post pIpC injection. ( B-I ) Box plots show distribution of data from 6 mice per group. ( B-D ) Mixed effects models were used to analyze these data, with Hb, HCT or RBC counts as the outcome variable, and time (pre- and post-pIpC), genotype and their interaction as fixed effects, and a mouse random effect to account for within-mouse correlation between repeated measurements. Fisher’s LSD approach was used, and pairwise comparison p -values were not adjusted. ( E-I ) Statistical analyses were performed using Mann-Whitney test. ( B-I ) Statistically significant p -values are reported. ns - not significant. See also supplemental figures 1 – 3 .

    Article Snippet: Mice were randomized into two treatment groups by hematocrit levels and body weight: 1) vehicle-control (5% DMSO, 10% Tween 80, 85% water) and 2) ULK1 inhibitor SBP-7455 (TargetMol) at 30mg/kg.

    Techniques: In Vivo, Knock-Out, Injection, Comparison, MANN-WHITNEY

    ( A ) Schematic illustration of the Ulk1 wild type versus Ulk1 knockout mouse MPN model used, and analyses performed. ( B ) Percentage of engraftment of CD45.2+ cells, ( C ) hemoglobin (Hb) levels, ( D ) hematocrit (HCT) percentage and ( E ) red blood cell (RBC) counts in peripheral blood of recipient mice are shown for two- and four-weeks post bone marrow transplant (BMT). ( F ) Percentage of GFP + BM cells four weeks post BMT of the recipient mice. ( G ) Percentage of GFP + ( G-i ) Ter119 med CD71 high proerythroblasts (R1), ( G-ii ) Pre-CFU-E, and ( G-iii ) PreMegE in the BM of recipient mice four weeks post BMT. ( H ) Spleen weight and ( I ) percentage of GFP + splenocytes four weeks post BMT of the recipient mice. ( J ) Percentage of GFP + ( J-i ) R1, ( J-ii ) R2 and ( J-iii ) R3+R4 cells in the spleen of recipient mice four weeks post BMT. ( B-E ) Data shown are means ± SD (n = 10 per group). Mixed effects models were used to analyze these data, with engraftment, Hb, HCT or RBC counts as the outcome variable, and time post-bone marrow transplant (BMT) (2 and 4 weeks), genotype and their interaction as fixed effects, and a mouse random effect to account for within-mouse correlation between repeated measurements. Fisher’s LSD approach was used, and pairwise comparison p -values were not adjusted. ( F-J ) Box plots show distribution of data from 10 mice per group. Statistical analyses were performed using Mann-Whitney test. ( B-J ) Statistically significant p -values are reported. See also supplemental figures 4 and 5 .

    Journal: Molecular and cellular biology

    Article Title: Loss of function mouse models reveal a novel regulatory function for ULK1 in myeloproliferative neoplasms

    doi: 10.1080/10985549.2025.2529837

    Figure Lengend Snippet: ( A ) Schematic illustration of the Ulk1 wild type versus Ulk1 knockout mouse MPN model used, and analyses performed. ( B ) Percentage of engraftment of CD45.2+ cells, ( C ) hemoglobin (Hb) levels, ( D ) hematocrit (HCT) percentage and ( E ) red blood cell (RBC) counts in peripheral blood of recipient mice are shown for two- and four-weeks post bone marrow transplant (BMT). ( F ) Percentage of GFP + BM cells four weeks post BMT of the recipient mice. ( G ) Percentage of GFP + ( G-i ) Ter119 med CD71 high proerythroblasts (R1), ( G-ii ) Pre-CFU-E, and ( G-iii ) PreMegE in the BM of recipient mice four weeks post BMT. ( H ) Spleen weight and ( I ) percentage of GFP + splenocytes four weeks post BMT of the recipient mice. ( J ) Percentage of GFP + ( J-i ) R1, ( J-ii ) R2 and ( J-iii ) R3+R4 cells in the spleen of recipient mice four weeks post BMT. ( B-E ) Data shown are means ± SD (n = 10 per group). Mixed effects models were used to analyze these data, with engraftment, Hb, HCT or RBC counts as the outcome variable, and time post-bone marrow transplant (BMT) (2 and 4 weeks), genotype and their interaction as fixed effects, and a mouse random effect to account for within-mouse correlation between repeated measurements. Fisher’s LSD approach was used, and pairwise comparison p -values were not adjusted. ( F-J ) Box plots show distribution of data from 10 mice per group. Statistical analyses were performed using Mann-Whitney test. ( B-J ) Statistically significant p -values are reported. See also supplemental figures 4 and 5 .

    Article Snippet: Mice were randomized into two treatment groups by hematocrit levels and body weight: 1) vehicle-control (5% DMSO, 10% Tween 80, 85% water) and 2) ULK1 inhibitor SBP-7455 (TargetMol) at 30mg/kg.

    Techniques: In Vivo, Knock-Out, Comparison, MANN-WHITNEY

    ( A ) Schematic illustration of the Jak2 V617F knock-in MPN transplant mouse model used, treatment regimen, and analyses performed. ( B ) Hemoglobin (Hb) levels, ( C ) hematocrit (HCT) percentage and ( D ) red blood cell (RBC) counts in peripheral blood of recipient mice are shown for each treatment group four weeks post treatment initiation. ( E ) Percentage of Ter119 med CD71 high proerythroblasts (R1), ( F ) Ter119 high CD71 high basophilic erythroblasts (R2) and ( G ) Ter119 high CD71 med late basophilic and polychromatophilic erythroblasts (R3) and Ter119 high CD71 low orthochromatophilic erythroblasts (R4) in the BM of recipient mice four weeks post treatment initiation. ( H ) Spleen weight and percentage of ( I ) R1, ( J ) R2 and ( K ) R3+R4 cells in the spleen of recipient mice four weeks post treatment initiation. ( B-K ) Box plots show distribution of data from 10 mice per group. Statistical analyses were performed using Mann-Whitney test. Statistically significant p -values are reported. See also supplemental figures 6 and 7 . ( L-M ) Cellular viability of JAK2 V617F -positive ( L ) HEL and ( M ) SET-2 cells treated with either DMSO-vehicle control (Ctrl) or with increasing doses of the ULK1 inhibitor SBP-7455 for five days, as indicated, was measured using WST-1 cell viability reagent. Data are expressed as percent cell viability relative to Ctrl-treated cells and represent means ± SEM of ( L ) four and ( M ) three independent experiments. IC50 values are shown. ( N ) Clonogenic capability of HEL cells treated with either vehicle-control (DMSO) or with increasing doses of the ULK1 inhibitor SBP-7455, as indicated. Data are expressed as percent colony formation relative to DMSO-treated cells (control) and represent means ± SEM of three independent experiments. Statistical analysis was performed using Welch’s ANOVA test that accounts for unequal variances followed by Dunnett’s T3 pairwise multiple comparisons test. Statistically significant p -values are reported. Test for linear trend based on the one-way ANOVA model showed a significant decrease in colony formation with increased dose of ULK1 inhibitor ( p <0.0001). See also supplemental figure 8 .

    Journal: Molecular and cellular biology

    Article Title: Loss of function mouse models reveal a novel regulatory function for ULK1 in myeloproliferative neoplasms

    doi: 10.1080/10985549.2025.2529837

    Figure Lengend Snippet: ( A ) Schematic illustration of the Jak2 V617F knock-in MPN transplant mouse model used, treatment regimen, and analyses performed. ( B ) Hemoglobin (Hb) levels, ( C ) hematocrit (HCT) percentage and ( D ) red blood cell (RBC) counts in peripheral blood of recipient mice are shown for each treatment group four weeks post treatment initiation. ( E ) Percentage of Ter119 med CD71 high proerythroblasts (R1), ( F ) Ter119 high CD71 high basophilic erythroblasts (R2) and ( G ) Ter119 high CD71 med late basophilic and polychromatophilic erythroblasts (R3) and Ter119 high CD71 low orthochromatophilic erythroblasts (R4) in the BM of recipient mice four weeks post treatment initiation. ( H ) Spleen weight and percentage of ( I ) R1, ( J ) R2 and ( K ) R3+R4 cells in the spleen of recipient mice four weeks post treatment initiation. ( B-K ) Box plots show distribution of data from 10 mice per group. Statistical analyses were performed using Mann-Whitney test. Statistically significant p -values are reported. See also supplemental figures 6 and 7 . ( L-M ) Cellular viability of JAK2 V617F -positive ( L ) HEL and ( M ) SET-2 cells treated with either DMSO-vehicle control (Ctrl) or with increasing doses of the ULK1 inhibitor SBP-7455 for five days, as indicated, was measured using WST-1 cell viability reagent. Data are expressed as percent cell viability relative to Ctrl-treated cells and represent means ± SEM of ( L ) four and ( M ) three independent experiments. IC50 values are shown. ( N ) Clonogenic capability of HEL cells treated with either vehicle-control (DMSO) or with increasing doses of the ULK1 inhibitor SBP-7455, as indicated. Data are expressed as percent colony formation relative to DMSO-treated cells (control) and represent means ± SEM of three independent experiments. Statistical analysis was performed using Welch’s ANOVA test that accounts for unequal variances followed by Dunnett’s T3 pairwise multiple comparisons test. Statistically significant p -values are reported. Test for linear trend based on the one-way ANOVA model showed a significant decrease in colony formation with increased dose of ULK1 inhibitor ( p <0.0001). See also supplemental figure 8 .

    Article Snippet: Mice were randomized into two treatment groups by hematocrit levels and body weight: 1) vehicle-control (5% DMSO, 10% Tween 80, 85% water) and 2) ULK1 inhibitor SBP-7455 (TargetMol) at 30mg/kg.

    Techniques: Inhibition, Activity Assay, In Vivo, Knock-In, MANN-WHITNEY, Control

    ( A-B ) Immunoblotting analysis of the indicated proteins in lysates from non-targeting (NT) control, Atg7 KO and Ulk1 KO Jak2 V617F -positive Ba/F3-EpoR + GFP-LC3-RFP-expressing cells. ( C ) Percentage of autophagy measured as percentage of GFP negative cells assessed by flow cytometry analyses of NT control, Atg7 KO and Ulk1 KO Jak2 V617F -positive Ba/F3-EpoR + GFP-LC3-RFP-expressing cells cultured under normal nutrient conditions (RPMI 1640 media supplemented with 10% FBS and 10 ng/mL of IL-3, no starvation) or under starvation conditions (RPMI 1640 media without serum and IL-3) for 48 hours. Scatter dot plot shows means ± SD. Statistical analysis was performed using Welch’s ANOVA test that accounts for unequal variances followed by Dunnett’s T3 pairwise multiple comparisons test. Statistically significant p -values are reported. ( D-F ) Immunoblotting analysis of the indicated proteins in lysates from ( D ) Cas9-control compared to ULK1 KO HEL cells and from ( E ) HEL cells treated with either DMSO-vehicle control (C), 5μM SBP-7455 (S), 100nM bafilomycin A1 (B) or with the combination of SBP-7455 and bafilomycin A1 (S+B) for 4 hours under either nutrient-starvation conditions (HBSS) or normal complete nutrient-conditions (RPMI). Immunoblots shown are representative of three independent experiments. ( F ) SET-2 cells treated with either DMSO-vehicle control (C), 5μM SBP-7455 (S), 100nM bafilomycin A1 (B) or with the combination of SBP-7455 and bafilomycin A1 (S+B) for 4 hours under either nutrient-starvation conditions (HBSS) or normal complete nutrient-conditions (RPMI). Immunoblots shown are representative of three independent experiments.

    Journal: Molecular and cellular biology

    Article Title: Loss of function mouse models reveal a novel regulatory function for ULK1 in myeloproliferative neoplasms

    doi: 10.1080/10985549.2025.2529837

    Figure Lengend Snippet: ( A-B ) Immunoblotting analysis of the indicated proteins in lysates from non-targeting (NT) control, Atg7 KO and Ulk1 KO Jak2 V617F -positive Ba/F3-EpoR + GFP-LC3-RFP-expressing cells. ( C ) Percentage of autophagy measured as percentage of GFP negative cells assessed by flow cytometry analyses of NT control, Atg7 KO and Ulk1 KO Jak2 V617F -positive Ba/F3-EpoR + GFP-LC3-RFP-expressing cells cultured under normal nutrient conditions (RPMI 1640 media supplemented with 10% FBS and 10 ng/mL of IL-3, no starvation) or under starvation conditions (RPMI 1640 media without serum and IL-3) for 48 hours. Scatter dot plot shows means ± SD. Statistical analysis was performed using Welch’s ANOVA test that accounts for unequal variances followed by Dunnett’s T3 pairwise multiple comparisons test. Statistically significant p -values are reported. ( D-F ) Immunoblotting analysis of the indicated proteins in lysates from ( D ) Cas9-control compared to ULK1 KO HEL cells and from ( E ) HEL cells treated with either DMSO-vehicle control (C), 5μM SBP-7455 (S), 100nM bafilomycin A1 (B) or with the combination of SBP-7455 and bafilomycin A1 (S+B) for 4 hours under either nutrient-starvation conditions (HBSS) or normal complete nutrient-conditions (RPMI). Immunoblots shown are representative of three independent experiments. ( F ) SET-2 cells treated with either DMSO-vehicle control (C), 5μM SBP-7455 (S), 100nM bafilomycin A1 (B) or with the combination of SBP-7455 and bafilomycin A1 (S+B) for 4 hours under either nutrient-starvation conditions (HBSS) or normal complete nutrient-conditions (RPMI). Immunoblots shown are representative of three independent experiments.

    Article Snippet: Mice were randomized into two treatment groups by hematocrit levels and body weight: 1) vehicle-control (5% DMSO, 10% Tween 80, 85% water) and 2) ULK1 inhibitor SBP-7455 (TargetMol) at 30mg/kg.

    Techniques: Inhibition, Western Blot, Control, Expressing, Flow Cytometry, Cell Culture

    ( A-B ) HEL cells were treated with either vehicle (DMSO, Ctrl), 5μM SBI-0206965 (SBI) or 5μM ULK101 for 6 hours followed by RNA-seq and analysis of transcript expression. ( A ) Heatmap of differentially expressed genes between treatment groups (adj. p val. < 0.01). ( B ) MA plot of genes significantly changed by drug-targeted inhibition of ULK1 in HEL cells versus control (adj. p val. < 0.01). In purple are represented up-regulated genes and in green are represented down-regulated genes. ( C and D ) Enriched ontology clusters for genes that are ( C ) increased or ( D ) decreased after drug-targeted inhibition of ULK1 in HEL cells. ( A-D ) Data are from 4 biological replicates per condition. See also supplemental figures 9 – 11 .

    Journal: Molecular and cellular biology

    Article Title: Loss of function mouse models reveal a novel regulatory function for ULK1 in myeloproliferative neoplasms

    doi: 10.1080/10985549.2025.2529837

    Figure Lengend Snippet: ( A-B ) HEL cells were treated with either vehicle (DMSO, Ctrl), 5μM SBI-0206965 (SBI) or 5μM ULK101 for 6 hours followed by RNA-seq and analysis of transcript expression. ( A ) Heatmap of differentially expressed genes between treatment groups (adj. p val. < 0.01). ( B ) MA plot of genes significantly changed by drug-targeted inhibition of ULK1 in HEL cells versus control (adj. p val. < 0.01). In purple are represented up-regulated genes and in green are represented down-regulated genes. ( C and D ) Enriched ontology clusters for genes that are ( C ) increased or ( D ) decreased after drug-targeted inhibition of ULK1 in HEL cells. ( A-D ) Data are from 4 biological replicates per condition. See also supplemental figures 9 – 11 .

    Article Snippet: Mice were randomized into two treatment groups by hematocrit levels and body weight: 1) vehicle-control (5% DMSO, 10% Tween 80, 85% water) and 2) ULK1 inhibitor SBP-7455 (TargetMol) at 30mg/kg.

    Techniques: Inhibition, Activity Assay, Gene Expression, RNA Sequencing, Expressing, Control

    ( A-E ) Scatter dot plots of PIM1 , ID2 , HES1 , CTR9 and PDCD2 expression in healthy individuals (normal, n = 11) and patients with ET (n = 47), PV (n = 28) and MF (n = 18). Data extracted from GSE5464672. Shown are means ± SEM of Log2 mRNA expression. Statistical analyses were performed using one-way ANOVA followed by Dunnett’s multiple comparisons adjustment comparing each MPN group vs. Normal group. Statistically significant p -values are reported. ( F-J ) mRNA expression of the indicated genes was assessed by qRT-PCR analysis for HEL cells treated for 6 hours with either vehicle (DMSO, Control) or SBP-7455 (SBP), as indicated. Data are means ± SEM from three independent experiments. Fold changes relative to control (dashed line) were calculated for each experimental replicate (SBP/DSMO), and fold changes were compared to FC=1 using a one-sample t-test, p values are reported. See also supplemental figure 12 .

    Journal: Molecular and cellular biology

    Article Title: Loss of function mouse models reveal a novel regulatory function for ULK1 in myeloproliferative neoplasms

    doi: 10.1080/10985549.2025.2529837

    Figure Lengend Snippet: ( A-E ) Scatter dot plots of PIM1 , ID2 , HES1 , CTR9 and PDCD2 expression in healthy individuals (normal, n = 11) and patients with ET (n = 47), PV (n = 28) and MF (n = 18). Data extracted from GSE5464672. Shown are means ± SEM of Log2 mRNA expression. Statistical analyses were performed using one-way ANOVA followed by Dunnett’s multiple comparisons adjustment comparing each MPN group vs. Normal group. Statistically significant p -values are reported. ( F-J ) mRNA expression of the indicated genes was assessed by qRT-PCR analysis for HEL cells treated for 6 hours with either vehicle (DMSO, Control) or SBP-7455 (SBP), as indicated. Data are means ± SEM from three independent experiments. Fold changes relative to control (dashed line) were calculated for each experimental replicate (SBP/DSMO), and fold changes were compared to FC=1 using a one-sample t-test, p values are reported. See also supplemental figure 12 .

    Article Snippet: Mice were randomized into two treatment groups by hematocrit levels and body weight: 1) vehicle-control (5% DMSO, 10% Tween 80, 85% water) and 2) ULK1 inhibitor SBP-7455 (TargetMol) at 30mg/kg.

    Techniques: Inhibition, Expressing, Quantitative RT-PCR, Control

    ( A-E ) qRT-PCR analysis of the indicated genes mRNA expression in murine c-kit + bone marrow Jak2 V617F/+ VavCre + cells from 3 mice treated for 6 hours with either vehicle (DMSO, Control) or 5μM SBP-7455 (SBP), as indicated. Data are means ± SD across three different mice. Fold changes were calculated relative to gene expression from one randomly selected vehicle control-treated mouse sample. Statistical analyses were performed using two-tailed unpaired t test with Welch’s correction. Statistically significant p -values are reported. ( F-J ) qRT-PCR analysis of the indicated genes mRNA expression in Cas9-control and ULK1 KO HEL cells, as indicated. Data are means ± SD across three independent experiments. Fold changes were calculated relative to gene expression from one randomly selected Cas9 control sample. Statistical analyses were performed using two-tailed unpaired t test with Welch’s correction. Statistically significant p -values are reported. See also supplemental figures 13 – 15 .

    Journal: Molecular and cellular biology

    Article Title: Loss of function mouse models reveal a novel regulatory function for ULK1 in myeloproliferative neoplasms

    doi: 10.1080/10985549.2025.2529837

    Figure Lengend Snippet: ( A-E ) qRT-PCR analysis of the indicated genes mRNA expression in murine c-kit + bone marrow Jak2 V617F/+ VavCre + cells from 3 mice treated for 6 hours with either vehicle (DMSO, Control) or 5μM SBP-7455 (SBP), as indicated. Data are means ± SD across three different mice. Fold changes were calculated relative to gene expression from one randomly selected vehicle control-treated mouse sample. Statistical analyses were performed using two-tailed unpaired t test with Welch’s correction. Statistically significant p -values are reported. ( F-J ) qRT-PCR analysis of the indicated genes mRNA expression in Cas9-control and ULK1 KO HEL cells, as indicated. Data are means ± SD across three independent experiments. Fold changes were calculated relative to gene expression from one randomly selected Cas9 control sample. Statistical analyses were performed using two-tailed unpaired t test with Welch’s correction. Statistically significant p -values are reported. See also supplemental figures 13 – 15 .

    Article Snippet: Mice were randomized into two treatment groups by hematocrit levels and body weight: 1) vehicle-control (5% DMSO, 10% Tween 80, 85% water) and 2) ULK1 inhibitor SBP-7455 (TargetMol) at 30mg/kg.

    Techniques: Inhibition, Quantitative RT-PCR, Expressing, Control, Gene Expression, Two Tailed Test